A-dmDT390-anti-CD3 immunotoxin

Drug Profile

A-dmDT390-anti-CD3 immunotoxin

Alternative Names: A-dmDT390-bisFv; A-dmDT390-bisFv(UCHT1); Anti-CD3 antibody-diphtheria toxin conjugate; Anti-CD3 bivalent antibody-diphtheria toxin conjugate; LAX-699; Recombinant anti-CDR-bi-single-chain-Fv-diptheria toxin fusion protein; Resimmune; UCHT-1-Angimmune

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Angimmune; University of Louisville
  • Class Immunotoxins; Peptides
  • Mechanism of Action Peptide elongation factor 2 inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cutaneous T cell lymphoma; Malignant melanoma

Most Recent Events

  • 20 Dec 2016 Angimmune plans a phase I/II trial for Melanoma (late-stage disease; Adjunctive therapy) in USA (NCT02990416)
  • 30 Nov 2016 Angimmune completes a phase II trial in Cutaneous T-cell lymphoma in USA (NCT00611208)
  • 22 Nov 2016 Angimmune terminates a phase-I/II clinical trial in Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease) in USA (Parenteral) (NCT01888081)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top